{"ModuleTitle": "Company Description", "CompanyName": "Seattle Genetics, Inc.", "Symbol": "SGEN", "Address": "21823 30TH DRIVE SE SUITE, BOTHELL, Washington, 98021, United States of America", "Phone": "4255274000", "Industry": "Biotechnology: Biological Products (No Diagnostic Substances)", "Sector": "Health Care", "Region": "North America", "CompanyDescription": "Seattle Genetics is a biotechnology company that develops and commercializes\r\ntherapies targeting cancer. We are commercializing ADCETRIS\u00ae, or brentuximab\r\nvedotin, for the trbreatment of certain CD30-expressing lymphomas, and PADCEVTM,\r\nor enfortumab vedotin-ejfv, for the treatment of certain metastatic urothelial\r\ncancers. We are also advancing a pipeline of novel therapies for solid tumors\r\nand blood-related cancers designed to address unmet medical needs and improve\r\ntreatment outcomes for patients. Many of our programs, including ADCETRIS and\r\nPADCEV, are based on our antibody-drug conjugate, or ADC, technology that\r\nutilizes the targeting ability of monoclonal antibodies to deliver cell-killing\r\nagents directly to cancer cells.\r\nADCETRIS is commercially available in more than 70 countries worldwide. We\r\ncommercialize ADCETRIS in the U.S.&nbsp;&nbsp;... <a href=\"http://secfilings.nasdaq.com/edgar_conv_html%2f2020%2f02%2f06%2f0001060736-20-000006.html#FIS_BUSINESS\" target=\"_blank\">More</a> ...&nbsp;&nbsp;\r\n", "KeyExecutives": [{"name": "Clay B. Siegall", "title": "Chairman, President & Chief Executive Officer"}, {"name": "Robert J. Lechleider", "title": "Senior Vice President-Clinical Development"}, {"name": "Roger D. Dansey", "title": "Chief Medical Officer"}, {"name": "Todd E. Simpson", "title": "Chief Financial Officer"}, {"name": "Vaughn B. Himes", "title": "Chief Technical Officer"}]}